Genesis Therapeutics

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into a strategic collaboration with Genesis Therapeutics Inc., an AI-driven drug development firm, to discover and develop innovative small-molecule therapies across a range of therapeutic targets. Under the terms of the agreement, Genesis will receive an…